Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.
The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.
ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.
Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.
The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。